

**MAGEA3 Antibody (C-term) Blocking Peptide**  
**Synthetic Peptide**  
**Catalog # BP6165a****Specification****MAGEA3 Antibody (C-term) Blocking Peptide - Product Information**Primary Accession [P43357](#)**MAGEA3 Antibody (C-term) Blocking Peptide - Additional Information****Gene ID** 4102**Other Names**

Melanoma-associated antigen 3, Antigen MZ2-D, Cancer/testis antigen 13, CT13, MAGE-3 antigen, MAGEA3, MAGE3

**Target/Specificity**

The synthetic peptide sequence is selected from the C-terminus of human MAGEA3.

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**MAGEA3 Antibody (C-term) Blocking Peptide - Protein Information****Name** MAGEA3**Synonyms** MAGE3**Function**

Proposed to enhance ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases. May enhance

**MAGEA3 Antibody (C-term) Blocking Peptide - Background**

MAGEA3 is a member of the MAGEA gene family. The members of this family have their entire coding sequences located in the last exon, and the encoded proteins show 50 to 80% sequence identity between each other. The promoters and first exons of the MAGEA genes show considerable variability, suggesting that the existence of this gene family enables the same function to be expressed under different transcriptional controls. The MAGEA genes are expressed at a high level in a number of tumors of various histologic types, and are silent in normal tissues with the exception of testis and placenta. The MAGEA genes are clustered on chromosome Xq28. They may be implicated in some hereditary disorders, such as dyskeratosis congenita.

**MAGEA3 Antibody (C-term) Blocking Peptide - References**

Guo, J., et al., Exp. Mol. Pathol. 74(2):140-147 (2003). Consogno, G., et al., Blood 101(3):1038-1044 (2003). Rogner, U.C., et al., Genomics 29(3):725-731 (1995). Gaugler, B., et al., J. Exp. Med. 179(3):921-930 (1994). van der Bruggen, P., et al., Science 254(5038):1643-1647 (1991).

ubiquitin ligase activity of TRIM28 and stimulate p53/TP53 ubiquitination by TRIM28. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzyme (E2) at the E3:substrate complex. May play a role in embryonal development and tumor transformation or aspects of tumor progression. In vitro promotes cell viability in melanoma cell lines. Antigen recognized on a melanoma by autologous cytolytic T-lymphocytes.

**Tissue Location**

Expressed in many tumors of several types, such as melanoma, head and neck squamous cell carcinoma, lung carcinoma and breast carcinoma, but not in normal tissues except for testes and placenta. Never expressed in kidney tumors, Leukemias and lymphomas

**MAGEA3 Antibody (C-term) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)